

Chapter 42

REFERENCES

1. Pasternak GW. Multiple opiate receptors: déjà vu all over again. *Neuropharmacol.* 2004;47:312.
2. Cadet P, Mantione KJ, Stefano GB. Molecular identification and functional expression of mu 3, a novel alternatively spliced variant of the human mu opiate receptor gene. *J Immunol.* 2003;170:5118.
3. Lötsch J, Geisslinger G. Are μ -opioid receptor polymorphisms important for clinical opioid therapy? *Trends Mol Sci.* 2005;11:82-89.
4. Law PY, Loh HH, Wei L-N. Insights into the receptor transcription and signaling: implications in opioid tolerance and dependence. *Neuropharmacology.* 2004;47:300.
5. Chou WY, Wang CH, Liu PH, et al. Human opioid receptor A118G polymorphism affects intravenous patient-controlled analgesia morphine consumption after total abdominal hysterectomy. *Anesthesiology.* 2006; 105:334-337.
6. Janicki PK, Schuler G, Francis D, et al. A genetic association study of the functional A118G polymorphism of the human mu-opioid receptor gene in patients with acute and chronic pain. *Anesth Analg.* 2006; 103:1011-1017.
7. Romberg RR, Olofsen E, Bijl H, et al. Polymorphism of mu-opioid receptor gene (OPRM1:c.118A>G) does not protect against opioid-induced respiratory depression despite reduced analgesic response. *Anesthesiology.* 2005;102:522-530.
8. Takemori AE, Ho BY, Naeseth JS, et al. Nor-binaltorphimine, a highly selective k-opioid antagonist in analgesic and receptor binding assays. *J Pharmacol Exp Ther.* 1988;246:255.
9. Paul D, Levison JA, Howard DH, et al. Naloxone benzoylhydrazone (NalBzoH) analgesia. *J Pharmacol Exp Ther.* 1990;255:769.
10. Goodman RR, Snyder SH, Kuhar MJ, et al. Differentiation of δ and μ opiate receptor localizations by light microscopic autoradiography. *Proc Natl Acad Sci U S A.* 1980;77:6239.
11. Porreca F, Heyman JS, Mosberg HI, et al. Role of mu and delta receptors in the supraspinal and spinal analgesic effects of [D-Pen²,D-Pen⁵]enkephalin in the mouse. *J Pharmacol Exp Ther.* 1987;241:393.
12. Smart D, Hirst RA, Hirota K, et al. The effects of recombinant rat mu-opioid receptor activation in CHO cells on phospholipase C, [Ca²⁺] and adenylyl cyclase. *Br J Pharmacol.* 1997;120:1165.
13. Gutstein HB, Rubie EA, Mansour A, et al. Opioid effects on mitogen-activated protein kinase signaling cascades. *Anesthesiology.* 1997;87:1118-1126.
14. Henry DJ, Grandy DK, Lester HA, et al. Kappa-opioid receptors couple to inwardly rectifying potassium channels when coexpressed by *Xenopus* oocytes. *Mol Pharmacol.* 1995;47:551-557.
15. Tallent M, Dichter MA, Bell GI, et al. The cloned kappa opioid receptor couples to an N-type calcium current in undifferentiated PC-12 cells. *Neuroscience.* 1994;63:1033-1040.
16. Mogil JS, Pasternak GW. The molecular and behavioral pharmacology of the orphanin FQ/nociceptin peptide and receptor family. *Pharmacol Rev.* 2001;53:381-415.
17. Zadina JE, Hackler L, Ge LJ, et al. A potent and selective endogenous agonist for the μ -opiate receptor. *Nature.* 1997;386:499-502.
18. Weitz CJ, Faull KF, Goldstein A. Synthesis of the skeleton of the morphine molecule by mammalian liver. *Nature.* 1987;330:674.
19. Donnerer J, Cardinale G, Coffey J, et al. Chemical characterization and regulation of endogenous morphine and codeine in the rat. *J Pharm Exp Ther.* 1987;242:583.
20. Advokat C. The role of descending inhibition in morphine-induced analgesia. *Trends Pharmacol Sci.* 1988;9:330.
21. Stein C, Comisel K, Haimerl E, et al. Analgesic effect of intra-articular morphine after arthroscopic knee surgery. *N Engl J Med.* 1991;325:1123.
22. Dickenson AH, Suzuki R. Opioids in neuropathic pain: clues from animal studies. *Eur J Pain.* 2005;9:113-116.
23. Eisenberg E, McNicol ED, Carr DB. Efficacy and safety of opioid agonists in the treatment of neuropathic pain of nonmalignant origin: systematic review and meta-analysis of randomized controlled trials. *JAMA.* 2005;293:3043-3052.
24. Ballantyne JC, Fleisher LA. Ethical issues in opioid prescribing for chronic pain. *Pain.* 2010;148:365-367.
25. Bailey PL, Wilbrink J, Zwanikken P, et al. Anesthetic induction with fentanyl. *Anesth Analg.* 1985;64:48.
26. Silbert BS, Rosow CE, Keegan CR, et al. The effect of diazepam on induction of anesthesia with alfentanil. *Anesth Analg.* 1986;65:71.
27. Sebel PS, Bovill JG, Wauquier A, et al. Effects of high-dose fentanyl anesthesia on the electroencephalogram. *Anesthesiology.* 1981;55:203.
28. Murkin JM, Moldenhaur CC, Hug CC Jr, et al. Absence of seizures during induction of anesthesia with high-dose fentanyl. *Anesth Analg.* 1984;63:489.

29. Szeto HH, Inturrisi CE, Houde R, et al. Accumulation of normeperidine, an active metabolite of meperidine in patients with renal failure or cancer. *Ann Intern Med.* 1977;86:738.
30. Milde LN, Milde JH, Gallagher WJ. Cerebral effects of fentanyl in dogs. *Br J Anaesth.* 1989;63:710.
31. Shupak RC, Harp JR. Comparison between high-dose sufentanil-oxygen and high-dose fentanyl-oxygen for neuroanesthesia. *Br J Anaesth.* 1985;57:375.
32. Keats AS. The effect of drugs on respiration in man. *Ann Rev Pharmacol Toxicol.* 1985;25:41.
33. Oertel BG, Felden L, Tran PV, et al. Selective antagonism of opioid-induced ventilatory depression by an ampakine molecule in humans without loss of analgesia. *Clin Pharmacol Ther.* 2010;87:204-211.
34. Weil JV, McCullough RE, Kline JS, et al. Diminished ventilatory response to hypoxia and hypercapnia after morphine in normal man. *N Engl J Med.* 1975;292:1103.
35. Forrest WH, Bellville JW. The effect of sleep plus morphine on the respiratory response to carbon dioxide. *Anesthesiology.* 1964;25:137.
36. Bernards CM, Knowlton SL, Schmidt DF, et al. Respiratory and sleep effects of remifentanyl in volunteers with moderate obstructive sleep apnea. *Anesthesiology.* 2009;110:41-49.
37. Benumof JL. Obstructive sleep apnea in the adult obese patient: implications for airway management. *J Clin Anesth.* 2001;13:144-156.
38. Cullen DJ. Obstructive sleep apnea and postoperative analgesia—a potentially dangerous combination. *J Clin Anesth.* 2001;13:83-85.
39. Becker LD, Paulson BA, Miller RD, et al. Biphasic respiratory depression after fentanyl-droperidol or fentanyl alone used to supplement nitrous oxide anesthesia. *Anesthesiology.* 1976;44:291.
40. Smith SM, Schroeder K, Fahey T. Over-the-counter medications for acute cough in children and adults in ambulatory settings. *Cochrane Database Syst Rev.* 2008;(1):CD001831.
41. Lee HK, Wang SC. Mechanism of morphine-induced miosis in the dog. *J Pharmacol Exp Ther.* 1975;192:415.
42. Dershwitz M, Walsh JL, Morishige RJ, et al. Pharmacokinetics and pharmacodynamics of inhaled versus intravenous morphine in healthy volunteers. *Anesthesiology.* 2000;93:619-628.
43. Kharasch ED, Walker A, Hoffer C, et al. Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimally invasive and noninvasive probes for hepatic and first-pass CYP3A activity. *J Clin Pharmacol.* 2005;45:1187-1197.
44. Lötsch J, Skarke C, Schmidt H, et al. The transfer half-life of morphine-6-glucuronide from plasma to effect site assessed by pupil size measurement in healthy volunteers. *Anesthesiology.* 2001;95:1329-1338.
45. Wang SC, Glaviano VV. Locus of emetic action of morphine and Hydergine in dogs. *J Pharmacol Exp Ther.* 1954;111:329.
46. Costello DJ, Borison HL. Naloxone antagonizes narcotic self-blockade of emesis in the cat. *J Pharmacol Exp Ther.* 1977;203:222.
47. Benthuisen JL, Smith NT, Sanford TJ, et al. Physiology of alfentanil-induced rigidity. *Anesthesiology.* 1986;64:440.
48. Sanford TJ Jr, Weinger MB, Smith NT, et al. Pretreatment with sedative-hypnotics, but not with nondepolarizing muscle relaxants, attenuates alfentanil-induced muscle rigidity. *J Clin Anesth.* 1994;6:473-480.
49. Scamman FL. Fentanyl-O₂-N₂O rigidity and pulmonary compliance. *Anesth Analg.* 1983;62:332.
50. Costall B, Fortune DH, Naylor RJ. Involvement of mesolimbic and extrapyramidal nuclei in the motor depressant action of narcotic drugs. *J Pharm Pharmacol.* 1978;30:566.
51. Weinger MB, Smith NT, Blasco TA, Koob GF. Brain sites mediating opiate-induced muscle rigidity in the rat: methyl-naloxonium mapping study. *Brain Res.* 1991;544:181.
52. Laubie M, Schmitt H, Vincent M. Vagal bradycardia produced by micro-injections of morphine-like drugs into the nucleus ambiguus in anesthetized dogs. *Eur J Pharmacol.* 1979;59:287.
53. Urthaler F, Isobe JH, James T. Direct and vagally mediated chronotropic effects of morphine studied by selective perfusion of the sinus node of awake dogs. *Chest.* 1975;68:222.
54. Deo SH, Barlow MA, Gonzalez L, et al. Cholinergic location of delta-opioid receptors in canine atria and SA node. *Am J Physiol Heart Circ Physiol.* 2008;294:H829-H838.
55. Saini V, Carr DB, Hagestad EL, et al. Antifibrillatory action of the narcotic agonist fentanyl. *Am Heart J.* 1988;115:598.
56. Henney RP, Vasko JS, Brawley RK, et al. The effects of morphine on the resistance and capacitance vessels of the peripheral circulation. *Am Heart J.* 1966;72:242.
57. Zelis R, Mansour EJ, Capone RJ, et al. The cardiovascular effects of morphine. The peripheral capacitance and resistance vessels in human subjects. *J Clin Invest.* 1974;54:1247.
58. Lowenstein E, Whiting RB, Bittar DA, et al. Local and neurally mediated effects of morphine on skeletal muscle vascular resistance. *J Pharmacol Exp Ther.* 1972;180:359.
59. O'Keefe RJ, Domalik-Wawrzynski L, Guerrero JL. Local and neurally mediated effects of sufentanil on canine skeletal muscle vascular resistance. *J Pharmacol Exp Ther.* 1987;242:699-706.
60. Leaman DM, Levenson L, Zelis R, et al. Effect of morphine on splanchnic blood flow. *Br Heart J.* 1978;40:569.
61. Green JF, Jackman AP, Krohm KA. Mechanism of morphine-induced shifts in blood volume between extracorporeal reservoir and the systemic circulation of the dog under conditions of constant blood flow and vena caval pressures. *Circ Res.* 1978;42:479.
62. Hsu HO, Hickey RF, Forbes AR. Morphine decreases peripheral vascular resistance and increases capacitance in man. *Anesthesiology.* 1979;50:98.
63. Ward JW, McGrath RL, Weil JV. Effects of morphine on the peripheral vascular response to sympathetic stimulation. *Am J Cardiol.* 1972;29:656.
64. Ebert TJ, Kotrly KJ, Madsen KE, et al. Fentanyl-diazepam anesthesia does not attenuate cardiopulmonary baroreflex-mediated vasoconstrictor responses to controlled hypovolemia in humans. *Anesth Analg.* 1988;67:548.
65. Ludwig LM, Patel HH, Gross GJ et al. Morphine enhances pharmacological preconditioning by isoflurane. *Anesthesiology.* 2003; 98:705-711.
66. Zhang Y, Irwin MG, Wong TM, et al. Remifentanyl preconditioning confers cardioprotection via cardiac kappa- and delta-opioid receptors. *Anesthesiology.* 2005;102:371-378.
67. McPherson BC, Yao ZY. Signal transduction of opioid-induced cardioprotection in ischemia-reperfusion. *Anesthesiology.* 2001;94:1082-1088.
68. Murphy GS, Szokol JW, Marymont JH, et al. Opioids and cardioprotection: the impact of morphine and fentanyl on

- recovery of ventricular function after cardiopulmonary bypass. *J Cardiothor Vasc Anesth.* 2006;20:493-502.
69. Jang Y, Xi J, Wang H, et al. Postconditioning prevents reperfusion injury by activating delta-opioid receptors. *Anesthesiology.* 2008;108:243-250.
 70. Weihrauch D, Krolikowski JG, Bienengraeber M, et al. Morphine enhances isoflurane-induced postconditioning against myocardial infarction: the role of phosphatidylinositol-3-kinase and opioid receptors in rabbits. *Anesth Analg.* 2005;101:942-949.
 71. Wong GTC, Li R, Jiang LL, Irwin MG. Remifentanyl postconditioning attenuates cardiac ischemia-reperfusion injury via kappa or delta opioid receptor activation. *Acta Anaesthesiol Scand.* 2010;54:510-518.
 72. Hartlage MAG, Theisen MM, de Oliveira NPM, et al. Kappa opioid receptor antagonism improves recovery from myocardial stunning in chronically instrumented dogs. *Anesth Analg.* 2006;103:822-832.
 73. Zhang SZ, Wang NF, Xu J, et al. Kappa-Opioid receptors mediate cardioprotection by remote preconditioning. *Anesthesiology.* 2006;105:550-556.
 74. Rosow CE, Moss J, Philbin DM, et al. Histamine release during morphine and fentanyl anesthesia. *Anesthesiology.* 1982;56:93.
 75. Philbin DM, Moss J, Akins CW, et al. The use of H₁ and H₂ histamine antagonists with morphine anesthesia: a double-blind study. *Anesthesiology.* 1981;55:292.
 76. Tharp MD, Kagey-Sobotka A, Fox CC, et al. Functional heterogeneity of human mast cells from different anatomic sites: In vitro responses to morphine sulfate. *J Allergy Clin Immunol.* 1987;79:646-653.
 77. Flacke JW, Flacke WE, Bloor BC, et al. Histamine release by four narcotics: a double-blind study in humans. *Anesth Analg.* 1987;66:723.
 78. Rosow CE, Philbin DM, Keegan CR, et al. Hemodynamics and histamine release during induction with sufentanil or fentanyl. *Anesthesiology.* 1984;60:489.
 79. Hermans JM, Ebertz JM, Hanifin JM, et al. Comparison of histamine release in human skin mast cells induced by morphine, fentanyl, and oxymorphone. *Anesthesiology.* 1985;62:124.
 80. Ballantyne JC, Loach AB, Carr DB. Itching after epidural and spinal opiates. *Pain.* 1988;33:149.
 81. Kurz A, Sessler DI. Opioid-induced bowel dysfunction: pathophysiology and potential new therapies. *Drugs.* 2003;63:649-671.
 82. Elkiweri IA, Zhang YL, Christians U, et al. Competitive substrates for P-glycoprotein and organic anion protein transporters differentially reduce blood organ transport of fentanyl and looperamide: pharmacokinetics and pharmacodynamics in Sprague-Dawley rats. *Anesth Analg.* 2009; 108:149-159.
 83. Radnay PA, Duncalf D, Novakovic M, et al. Common bile duct pressure changes after fentanyl, morphine, meperidine, butorphanol and naloxone. *Anesth Analg.* 1984;63:441.
 84. Dray A, Metsch R. Opioids and central inhibition of urinary bladder motility. *Eur J Pharmacol.* 1984;98:155.
 85. Rosow CE, Gomery P, Chen TY, et al. Reversal of opioid-induced bladder dysfunction by intravenous naloxone and methylnaltrexone. *Clin Pharmacol Ther.* 2007;82:48-53.
 86. Aloisi AM, Ceccarelli I, Fiorenzani P, et al. Aromatase and 5 alpha reductase gene expression: modulation by pain and morphine treatment in male rats. *Mol Pain.* 2010;6:69.
 87. Bauchat JR. Neuraxial morphine and oral herpes reactivation in the obstetric population. *Anesth Analg.* 2010;111:1238-1241.
 88. Wei G, Moss J, Yuan CS. Opioid-induced immunosuppression. In: Yuan CS, ed. *Handbook of Opioid Bowel Syndrome.* New York, NY: Haworth Medical Press; 2005:45-57.
 89. Gaveriaux-Ruff C, Matthes HW, Peluso J, et al. Abolition of morphine-induced immunosuppression in mice lacking the μ -opioid receptor gene. *Proc Natl Acad Sci U S A.* 1998;95:6326-6330.
 90. Way WL, Costley EC, Way EL. Respiratory sensitivity of the newborn infant to meperidine and morphine. *Clin Pharmacol Ther.* 1965;6:454.
 91. Hinova A, Fernando R. Systemic remifentanyl for labor analgesia. *Anesth Analg.* 2009;109:1925-1929.
 92. Vinik HR, Kissin I. Rapid development of tolerance to analgesia during remifentanyl infusion in humans. *Anesth Analg.* 1998;86:1307-1311.
 93. Gustorff B, Nahlik G, Hoerauf KH, et al. The absence of acute tolerance during remifentanyl infusion in volunteers. *Anesth Analg.* 2002;94:1223-1228.
 94. Schraag S, Checketts MR, Kenny GN. Lack of rapid development of opioid tolerance during alfentanil and remifentanyl infusions for postoperative pain. *Anesth Analg.* 1999;89:753-757.
 95. Vadalouca A, Moka E, Argyra E, Sikioti P, Siafaka I. Opioid rotation in patients with cancer: a review of the literature. *J Opioid Manag.* 2008; 4:213-250.
 96. Bohn LM, Lefkowitz RJ, Gainetdinov RR, et al. Enhanced morphine analgesia in mice lacking beta-arrestin 2. *Science.* 1999;286:2495-2498.
 97. Gilron I, Biederman J, Jhamandas K, Hong M. Gabapentin blocks and reverses antinociceptive morphine tolerance in the rat paw-pressure and tail-flick tests. *Anesthesiology.* 2003;98:1288-1292.
 98. Price DD, Mayer DJ, Mao J, Caruso FS. NMDA-receptor antagonists and opioid receptor interactions as related to analgesia and tolerance. *J Pain Symptom Manage.* 2000;19:S7-S11.
 99. King T, Ossipov MH, Wanderah TW, et al. Is paradoxical pain induced by sustained opioid exposure an underlying mechanism of opioid antinociceptive tolerance? *Neurosignals.* 2005;14:194-205.
 100. Porter J, Jick H. Addiction rare in patients treated with narcotics. *N Engl J Med.* 1980;302:123.
 101. Okie S. A flood of opioids, a rising tide of deaths. *N Engl J Med.* 2010; 363:1981-1985.
 102. Gasche Y, Daali Y, Fathi M, et al. Codeine intoxication associated with ultrarapid CYP2D6 metabolism. *N Engl J Med.* 2004; 351:2827-2831.
 103. Kaufman JJ, Semo NM, Koski WS. Microelectrometric titration measurement of the pK_as and partition and drug distribution coefficients of narcotics and narcotic antagonists and their pH and temperature dependence. *J Med Chem.* 1975;18:647.
 104. Roy SD, Flynn GL. Solubility and related physicochemical properties of narcotic analgesics. *Pharm Res.* 1988;5:580-586.
 105. Letrent SP, Pollack GM, Brouwer KR, et al. Effects of a potent and specific P-glycoprotein inhibitor on the blood-brain barrier distribution and antinociceptive effect of morphine in the rat. *Drug Metab Dispos.* 1999;27:827-834.
 106. Romberg R, Olofsen E, Sarton E, et al. Pharmacodynamic effect of morphine-6-glucuronide versus morphine on hypoxic and

- hypercapnic breathing in healthy volunteers. *Anesthesiology*. 2003;99:788-798.
107. Romberg R, Olofsen E, Sarton E, et al. Pharmacokinetic-pharmacodynamic modeling of morphine-6-glucuronide-induced analgesia in healthy volunteers: absence of sex differences. *Anesthesiology*. 2004;100:120-133.
 108. Skarke C, Langer M, Jarrar M, et al. Probenecid interacts with the pharmacokinetics of morphine-6-glucuronide in humans. *Anesthesiology*. 2004;101:1394-1399.
 109. Skarke C, Darimont J, Schmidt H, et al. Analgesic effects of morphine and morphine-6-glucuronide in a transcutaneous electrical pain model in healthy volunteers. *Clin Pharmacol Ther*. 2003;73:107-121.
 110. Angst MS, Buhner M, Lotsch J. Insidious intoxication after morphine treatment in renal failure: delayed onset of morphine-6-glucuronide action. *Anesthesiology*. 2000;92:1473-1476.
 111. Hug CC Jr, Murphy MR, Rigel EP, et al. Pharmacokinetics of morphine injected intravenously into the anesthetized dog. *Anesthesiology*. 1981;54:38.
 112. Mather LE, Tucker GT, Pfulg AE, et al. Meperidine kinetics in man: intravenous injection in surgical patients and volunteers. *Clin Pharmacol Ther*. 1975;17:21.
 113. Verbeeck RK, Branch RA, Wilkinson GR. Meperidine disposition in man: influence of urinary pH and route of administration. *Clin Pharmacol Ther*. 1981;30:619.
 114. Paris A, Ohlendorf C, Marquardt M, et al. The effect of meperidine on thermoregulation in mice: involvement of α_2 -adrenoceptors. *Anesth Analg*. 2005;100:102-106.
 115. Gillman PK. Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. *Br J Anaesth*. 2005;95:434-441.
 116. Austin KL, Stapleton JV, Mather LE. Relationship between blood meperidine concentrations and analgesic response: a preliminary report. *Anesthesiology*. 1980;53:460.
 117. Ausems ME, Hug CC Jr, Stanski DR, et al. Plasma concentrations of alfentanil required to supplement nitrous oxide anesthesia for general surgery. *Anesthesiology*. 1986;65:362.
 118. Coda B, Tanaka A, Jacobson RC, et al. Hydromorphone analgesia after intravenous bolus administration. *Pain*. 1997;71:41-48.
 119. Murray A, Hagen NA. Hydromorphone. *J Pain Symptom Manage*. 2005;29:S57-S66.
 120. Adams MP, Ahdieh H. Single- and multiple-dose pharmacokinetic and dose-proportionality study of oxymorphone immediate-release tablets. *Drugs R D*. 2005;6:91-99.
 121. Scott JC, Ponganis KV, Stanski DR. EEG quantitation of narcotic effect: the comparative pharmacodynamics of fentanyl and alfentanil. *Anesthesiology*. 1985;62:234.
 122. McClain DA, Hug CC Jr. Intravenous fentanyl kinetics. *Clin Pharmacol Ther*. 1980;28:106.
 123. Murphy MR, Olson WA, Hug CC Jr. Pharmacokinetics of 3H-fentanyl in the dog anesthetized with enflurane. *Anesthesiology*. 1979;50:13.
 124. Bower S, Hull CJ. Comparative pharmacokinetics of fentanyl and alfentanil. *Br J Anaesth*. 1982;54:871.
 125. Shafer A, Sung ML, White PF. Pharmacokinetics and pharmacodynamics of alfentanil infusions during general anesthesia. *Anesth Analg*. 1986;65:1021.
 126. Bjorkman S, Stanski DR, Verotta D, et al. Comparative tissue concentration—profiles of fentanyl and alfentanil in man predicted from tissue-to-blood partition data obtained in rats. *Anesthesiology*. 1990;72:865.
 127. Okutani R, Philbin DM, Rosow CE, et al. Effect of hypothermic hemodilutional cardiopulmonary bypass on plasma sufentanil and catecholamine concentrations in humans. *Anesth Analg*. 1988;67:667.
 128. Westmoreland CL, Hoke JF, Sebel PS, et al. Pharmacokinetics of remifentanyl (GI87084B) and its major metabolite (GI90291) in patients undergoing elective inpatient surgery. *Anesthesiology*. 1993;79:893.
 129. Dershwitz M, Randel GI, Rosow CE, et al. Initial clinical experience with remifentanyl, a new opioid metabolized by esterases. *Anesth Analg*. 1995;81:619.
 130. Dershwitz M, Hoke JF, Rosow CE, et al. Pharmacokinetics and pharmacodynamics of remifentanyl in volunteer subjects with severe liver disease. *Anesthesiology*. 1996;84:812.
 131. Dershwitz M, Rosow CE. The pharmacokinetics and pharmacodynamics of remifentanyl in volunteers with severe hepatic or renal dysfunction. *J Clin Anesth*. 1996;8:88S.
 132. Inturrisi CE. Pharmacology of methadone and its isomers. *Minerva Anestesiol*. 2005;71:435-437.
 133. Kharasch ED. Intraoperative methadone: rediscovery, reappraisal, and reinvigoration? *Anesth Analg*. 2011;112:13-16.
 134. Grond S, Sablotzki A. Clinical pharmacology of tramadol. *Clin Pharmacokinet*. 2004;43:879-923.
 135. Stamer UM, Stuber F, Muders T, Musshoff F. Respiratory depression with tramadol in a patient with renal impairment and CYP2D6 gene duplication. *Anesth Analg*. 2008;107:926-929.
 136. Marincsak R, Toth BI, CZifra G, et al. The analgesic drug, tramadol, acts as an agonist of the transient receptor potential vanilloid-1. *Anesth Analg*. 2008;106:1890-1896.
 137. Gray TC, Rees GJ. The role of apnoea in anaesthesia for major surgery. *Br Med J*. 1952;2:891.
 138. Neff W, Mayer EC, de la Luz Perales M. Nitrous oxide and oxygen anesthesia with curare relaxation. *Calif Med*. 1947;66:67.
 139. De Castro J, Mundeeler R. Anesthésie sans barbituriques: la neuroleptanalgesie. *Anesth Analg (Paris)*. 1959;16:1022.
 140. Martin DE, Rosenberg H, Aukburg SJ, et al. Low-dose fentanyl blunts circulatory responses to tracheal intubation. *Anesth Analg*. 1982;61:680.
 141. Ben-Shlomo I, abd-el-Khalim H, Ezry J, et al. Midazolam acts synergistically with fentanyl for induction of anesthesia. *Br J Anaesth*. 1990;64:45.
 142. Kissin I, Vinik HR, Castillo R, et al. Alfentanil potentiates midazolam-induced unconsciousness in subanalgesic doses. *Anesth Analg*. 1990;71:65.
 143. Lang E, Kapila A, Shlugman D, et al. Reduction of isoflurane minimal alveolar concentration by remifentanyl. *Anesthesiology*. 1996;85:721-728.
 144. Murphy MR, Hug CC Jr. The enflurane sparing effect of morphine, butorphanol and nalbuphine. *Anesthesiology*. 1982;57:489-492.
 145. Scott JC, Stanski DR. Decreased fentanyl and alfentanil dose requirements with age. A simultaneous pharmacokinetic and pharmacodynamic evaluation. *J Pharmacol Exp Ther*. 1987;240:159.
 146. Aubrun F, Monsel S, Langeron O, et al. Postoperative titration of intravenous morphine in the elderly patient. *Anesthesiology*. 2002;96:17-23.

147. Sarton E, Olofsen E, Romberg R, et al. Sex differences in morphine analgesia: an experimental study in healthy volunteers. *Anesthesiology*. 2000;93:1245-1254.
148. Tegeder I, Löscht J, Geisslinger G. Pharmacokinetics of opioids in liver disease. *Clin Pharmacokinet*. 1999;37:17-40.
149. Davies G, Kingswood C, Street M. Pharmacokinetics of opioids in renal dysfunction. *Clin Pharmacokinet*. 1996;31:410-422.
150. Lowenstein E, Hallowell P, Levine FH, et al. Cardiovascular response to large doses of intravenous morphine in man. *N Engl J Med*. 1969;281:1389.
151. Stanley TH, Webster LR. Anesthetic requirements and cardiovascular effects of fentanyl-oxygen and fentanyl-diazepam-oxygen anesthesia in man. *Anesth Analg*. 1978;57:411.
152. Bovill JG, Sebel PS, Fiolet JW. The influence of sufentanil on endocrine and metabolic responses to cardiac anesthesia. *Anesth Analg*. 1983;62:391.
153. Mummaneni N, Rao TLK, Montoya A. Awareness and recall with high-dose fentanyl-oxygen anesthesia. *Anesth Analg*. 1980;59:948.
154. Philbin DM, Rosow CE, Schneider RC, et al. Fentanyl and sufentanil anesthesia revisited: how much is enough? *Anesthesiology*. 1990;73:5.
155. Tomicsek RC, Rosow CE, Philbin DM, et al. Diazepam-fentanyl interaction—hemodynamic and hormonal effects in coronary artery surgery. *Anesth Analg*. 1983;62:881.
156. Wynands JE, Wong P, Whalley DG, et al. Oxygen-fentanyl anesthesia in patients with poor left ventricular function: hemodynamics and plasma fentanyl concentrations. *Anesth Analg*. 1983;62:476.
157. Clark RB, Beard AG, Barclay DL. Naloxone in the newborn infant. *Anesth Rev*. 1975;(Dec):9.
158. Gueneron JP, Ecoffey C, Carli P, et al. Effect of naloxone infusion on analgesia and respiratory depression after epidural fentanyl. *Anesth Analg*. 1988;67:35.
159. Mills CA, Flacke JW, Miller JD, et al. Cardiovascular effects of fentanyl reversal by naloxone at varying arterial carbon dioxide tensions in dogs. *Anesth Analg*. 1988;67:730.
160. Partridge L, Ward CF. Pulmonary edema following low-dose naloxone administration. *Anesthesiology*. 1986;65:709.
161. Srisurapanont M, Jarusuraisin N. Opioid antagonists for alcohol dependence. *Cochrane Database Syst Rev*. 2005;25:CD001867.
162. Boyd TA, Yuan CS. Methylnaltrexone: investigations in treating opioid bowel dysfunction. In: Yuan CS, ed. *Handbook of Opioid Bowel Syndrome*. New York, NY: Haworth Medical Press; 2005:197-221.
163. Moss JM, Rosow CE. Development of peripheral opioid antagonists: new insights into opioid effects. *Mayo Clin Proc*. 2008; 83:1116-1130.
164. Yuan CS, Foss JF, O'Connor, et al. Methylnaltrexone prevents morphine-induced delay in oral-cecal transit time without affecting analgesia: a double-blind randomized placebo-controlled trial. *Clin Pharmacol Ther*. 1996;59:469-475.
165. Yuan CS, Foss JF, Osinski J, et al. The safety and efficacy of oral methylnaltrexone in preventing morphine-induced delay in oral-cecal transit time. *Clin Pharmacol Ther*. 1997;61:467-475.
166. Foss JF, Schmidt WK. Management of opioid-induced bowel dysfunction and postoperative ileus: potential role of alvimopan. In: Yuan CS, ed. *Handbook of Opioid Bowel Syndrome*. New York, NY: Haworth Medical Press; 2005:223-249.
167. Wolff BG, Michelassi F, Gerkin TM, et al. Alvimopan, a novel, peripherally acting mu opioid antagonist: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial of major abdominal surgery and postoperative ileus. *Ann Surg*. 2004;240:728-735.
168. Rance MJ. Multiple opiate receptors—their occurrence and significance. *Clin Anaesthesiol*. 1983;1:183.
169. Goodman RR, Snyder SH. Autoradiographic localization of kappa opiate receptors to deep layers of the cerebral cortex may explain unique sedative and analgesic effects. *Life Sci*. 1982;31:1291.
170. Dershwitz M, Rosow CE, DiBiase PM, et al. Comparison of the sedative effects of butorphanol and midazolam. *Anesthesiology*. 1991;74:717.
171. Gal TJ, DiFazio CA, Moscicki J. Analgesic and respiratory depressant activity of nalbuphine: a comparison with morphine. *Anesthesiology*. 1982;57:367.
172. Nagashima H, Karamanian A, Malovany R, et al. Respiratory and circulatory effects of intravenous butorphanol and morphine. *Clin Pharmacol Ther*. 1976;19:738.
173. Yassen A, Olofsen E, van Dorp E, et al. Mechanism-based pharmacokinetic-pharmacodynamic modeling of the reversal of buprenorphine-induced respiratory depression by naloxone: a study in healthy volunteers. *Clin Pharmacokinet*. 2007;46: 965-980.
174. McCammon RL, Stoelting RK, Madura JA. Effects of butorphanol nalbuphine and fentanyl on intrabiliary tract dynamics. *Anesth Analg*. 1984;63:139.
175. Tigerstedt I, Turunen M, Tammisto T, et al. The effect of buprenorphine and oxycodone on the intracholedochal passage pressure. *Acta Anaesth Scand*. 1981;25:99.
176. Popio KA, Jackson DH, Ross AM, et al. Hemodynamic and respiratory effects of morphine and butorphanol. *Clin Pharmacol Ther*. 1978;23:281.
177. Jaffe RD, Moldenhauer CC, Hug CC Jr, et al. Nalbuphine antagonism of fentanyl-induced ventilatory depression: a randomized trial. *Anesthesiology*. 1988;68:254.
178. Preston KL, Bigelow GE, Liebson IA. Butorphanol precipitated withdrawal in opioid dependent human volunteers. *J Pharmacol Exp Ther*. 1988;246:441.
179. Fudala PJ, Bridge TP, Herbert S, et al. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. *N Engl J Med*. 2003;349: 949-958.
180. Bryson EO, Lipson S, Gevirtz C. Anesthesia for patients on buprenorphine. *Anesthesiol Clin*. 2010;28:611-617.